NCT00171938View on ClinicalTrials.gov

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Glioblastoma
Interventions
DRUG

imatinib mesylate

Trial Locations (1)

Unknown

Rio Grande

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY